Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) shares rose 1.5% on Thursday . The company traded as high as $2.75 and last traded at $2.72. Approximately 24,774 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 154,089 shares. The stock had previously closed at $2.68.
Pyxis Oncology Stock Performance
The company’s 50 day moving average is $2.56 and its 200 day moving average is $4.15.
Pyxis Oncology (NASDAQ:PYXS – Get Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.35). Analysts predict that Pyxis Oncology, Inc. will post -3.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pyxis Oncology
Pyxis Oncology Company Profile
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.